Wedbush Forecasts Arvinas’ Q1 Earnings (NASDAQ:ARVN)

Arvinas, Inc. (NASDAQ:ARVN) – Research analysts at Wedbush raised their Q1 2025 EPS estimates for Arvinas in a note issued to investors on Wednesday, March 12th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.76) per share for the quarter, up from their prior forecast of ($0.93). Wedbush currently has a “Neutral” rating and a $12.00 target price on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share. Wedbush also issued estimates for Arvinas’ Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.09) EPS, FY2026 earnings at ($2.89) EPS, FY2027 earnings at ($2.95) EPS, FY2028 earnings at ($3.63) EPS and FY2029 earnings at ($3.43) EPS.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period last year, the firm earned ($2.53) earnings per share.

A number of other equities research analysts also recently issued reports on the stock. Guggenheim lowered their target price on shares of Arvinas from $57.00 to $32.00 and set a “buy” rating for the company in a report on Thursday, March 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Arvinas in a report on Friday, February 7th. Stifel Nicolaus lowered their target price on shares of Arvinas from $63.00 to $51.00 and set a “buy” rating for the company in a report on Wednesday, February 12th. The Goldman Sachs Group downgraded shares of Arvinas from a “buy” rating to a “neutral” rating and lowered their target price for the company from $70.00 to $15.00 in a report on Thursday, March 13th. Finally, BTIG Research started coverage on shares of Arvinas in a report on Tuesday, December 10th. They issued a “buy” rating and a $69.00 target price for the company. Five research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, Arvinas has an average rating of “Moderate Buy” and an average target price of $37.47.

Arvinas Stock Performance

Arvinas stock opened at $8.42 on Monday. Arvinas has a 1 year low of $7.91 and a 1 year high of $44.85. The firm has a 50 day moving average price of $16.87 and a 200 day moving average price of $21.59. The company has a market cap of $579.06 million, a price-to-earnings ratio of -3.04 and a beta of 1.95.

Institutional Trading of Arvinas

Several institutional investors have recently added to or reduced their stakes in ARVN. Intech Investment Management LLC acquired a new stake in Arvinas in the third quarter valued at $350,000. Algert Global LLC raised its holdings in Arvinas by 278.1% in the third quarter. Algert Global LLC now owns 168,061 shares of the company’s stock valued at $4,139,000 after acquiring an additional 123,613 shares in the last quarter. FMR LLC raised its holdings in Arvinas by 7.6% in the third quarter. FMR LLC now owns 2,883,604 shares of the company’s stock valued at $71,023,000 after acquiring an additional 204,317 shares in the last quarter. Quantbot Technologies LP raised its holdings in shares of Arvinas by 147.3% during the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after purchasing an additional 2,601 shares during the period. Finally, PEAK6 Investments LLC raised its holdings in shares of Arvinas by 42.9% during the third quarter. PEAK6 Investments LLC now owns 15,000 shares of the company’s stock worth $369,000 after purchasing an additional 4,500 shares during the period. 95.19% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO John G. Houston sold 31,338 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the sale, the chief executive officer now directly owns 1,157,480 shares of the company’s stock, valued at $19,353,065.60. This represents a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Ian Taylor sold 9,020 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the sale, the insider now directly owns 159,121 shares in the company, valued at $2,658,911.91. This represents a 5.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 41,572 shares of company stock worth $695,030. 5.23% of the stock is currently owned by company insiders.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.